发明名称 | Crystalline forms of a purine derivative | ||
摘要 | The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumor activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms. | ||
申请公布号 | US9573951(B2) | 申请公布日期 | 2017.02.21 |
申请号 | US201414524686 | 申请日期 | 2014.10.27 |
申请人 | Cyclacel Limited | 发明人 | Skead Benjamin Mark;Worrall Christopher Peter;Atherton Jonathan Charles Christian;Northen Julian Scott;Fernandes Philippe |
分类号 | C07D473/00;C07D473/16;G01F1/115;G01P3/48;G01P5/07;A61K31/52;C07C51/41;C07C57/145;C07C57/15;C07C59/245;C07C59/255;C07C59/265;C07C65/05;C07C303/32;C07C309/04;C07C309/29 | 主分类号 | C07D473/00 |
代理机构 | Nelson Mullins Riley & Scarborough LLP | 代理人 | Nelson Mullins Riley & Scarborough LLP ;Kanik Cynthia L.;Gastonguay Adam J. |
主权项 | 1. A crystalline form of compound (I), wherein said compound is in the form of the free base and which is characterized by an x-ray powder diffraction pattern having two or more diffraction peaks at 2[theta] values selected from 7.53±0.2, 9.60±0.2, 10.22±0.2, 11.29±0.2, 11.66±0.2, 12.26±0.2, 12.62±0.2, 13.17±0.2, 14.06±0.2, 14.85±0.2, 15.15±0.2, 15.57±0.2, 16.99±0.2, 17.68±0.2, 18.30±0.2, 18.39±0.2, 18.63±0.2, 18.97±0.2, 19.32±0.2 and 20.20±0.2. | ||
地址 | London GB |